Tags

Type your tag names separated by a space and hit enter

[Advances in the medical treatment of Parkinson's disease].
Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S22-5.PR

Abstract

Parkinson's disease (PD) is a common progressive neurodegenerative disorder. Dopamine replacement therapy considerably reduces motor handicap. Although levodopa continues as the gold standard for efficacy, its chronic use is associated with potentially disabling motor complications. Strategies to treat levodopa-related motor complications are only partially effective. Best results are currently achieved with invasive strategies via subcutaneous (s.c.) or intraduodenal delivery of apomorphine or levodopa, or deep brain stimulation of the subthalamic nucleus. This presentation will develop the current treatment principles for PD: (1) L-dopa does not accelerate disease progression, (2) no treatment modality exerts neuroprotective effects, (3) L-dopa is more effective than dopamine agonists in alleviating motor symptoms and improving the activities of daily living (ADL) score, in parkinsonian patients, (4) Treatment with dopamine agonist is associated with fewer motor complications than L-dopa. (5) Dopamine agonist therapy is associated with more frequent adverse events than L-dopa therapy, such as hallucinations and somnolence. There is no evidence of a long-term benefit with initial dopamine agonist therapy.

Authors+Show Affiliations

Neurología, Centro de trastornos del Movimiento, Facultad de Ciencias Médicas, Universidad de Santiago de Chile, Chile. chanapedro@gmail.com

Pub Type(s)

English Abstract
Journal Article
Review

Language

spa

PubMed ID

20082996

Citation

Chaná, Pedro. "[Advances in the Medical Treatment of Parkinson's Disease]." Parkinsonism & Related Disorders, vol. 15 Suppl 3, 2009, pp. S22-5.
Chaná P. [Advances in the medical treatment of Parkinson's disease]. Parkinsonism Relat Disord. 2009;15 Suppl 3:S22-5.
Chaná, P. (2009). [Advances in the medical treatment of Parkinson's disease]. Parkinsonism & Related Disorders, 15 Suppl 3, S22-5. https://doi.org/10.1016/S1353-8020(09)70773-4
Chaná P. [Advances in the Medical Treatment of Parkinson's Disease]. Parkinsonism Relat Disord. 2009;15 Suppl 3:S22-5. PubMed PMID: 20082996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Advances in the medical treatment of Parkinson's disease]. A1 - Chaná,Pedro, PY - 2010/1/20/entrez PY - 2010/1/30/pubmed PY - 2010/4/1/medline SP - S22 EP - 5 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 15 Suppl 3 N2 - Parkinson's disease (PD) is a common progressive neurodegenerative disorder. Dopamine replacement therapy considerably reduces motor handicap. Although levodopa continues as the gold standard for efficacy, its chronic use is associated with potentially disabling motor complications. Strategies to treat levodopa-related motor complications are only partially effective. Best results are currently achieved with invasive strategies via subcutaneous (s.c.) or intraduodenal delivery of apomorphine or levodopa, or deep brain stimulation of the subthalamic nucleus. This presentation will develop the current treatment principles for PD: (1) L-dopa does not accelerate disease progression, (2) no treatment modality exerts neuroprotective effects, (3) L-dopa is more effective than dopamine agonists in alleviating motor symptoms and improving the activities of daily living (ADL) score, in parkinsonian patients, (4) Treatment with dopamine agonist is associated with fewer motor complications than L-dopa. (5) Dopamine agonist therapy is associated with more frequent adverse events than L-dopa therapy, such as hallucinations and somnolence. There is no evidence of a long-term benefit with initial dopamine agonist therapy. SN - 1873-5126 UR - https://www.unboundmedicine.com/medline/citation/20082996/[Advances_in_the_medical_treatment_of_Parkinson's_disease]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(09)70773-4 DB - PRIME DP - Unbound Medicine ER -